Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation develops high-performance scientific instruments and analytical and diagnostic solutions for life science, applied, biopharma, microscopy, nanoanalysis, industrial, cleantech and semiconductor metrology markets.
Recurring news for BRKR includes earnings updates for Bruker Scientific Instruments and Bruker Energy & Supercon Technologies, product launches across NMR, microbiology, infection diagnostics, spatial biology and AFM-IR spectroscopy, and governance changes. Company announcements also cover platforms such as MALDI Biotyper, IR Biotyper, MyGenius PRO, GeoMx, CellScape, CosMx and Dimension IconIR.
Bruker (Nasdaq: BRKR) has successfully installed a 1.2 GHz NMR spectrometer at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin, accepted in Q2 2024. This advanced system will significantly enhance research capabilities in structural biology, pharmacology, and cellular biology by providing detailed insights into biomolecular structures and functions. The 1.2 GHz NMR system is expected to enable significant advancements in the understanding of intrinsically disordered proteins, which play critical roles in diseases like cancer and infectious diseases. It will support the characterization of novel active compounds and mechanisms of action, aiding in drug development efforts. FMP is already equipped with eleven NMR systems, and this latest addition marks a substantial evolution in its research capabilities. Key figures at FMP, including Dr. Peter Schmieder and Professors Hartmut Oschkinat and Adam Lange, emphasize the transformative potential of this technology in their research endeavors. Bruker expresses its commitment to supporting groundbreaking discoveries at FMP.
Cellens, an early-stage cancer diagnostic company, announced a collaboration with Bruker BioAFM to develop the first clinical diagnostic tests using multi-parametric, single-cell biophysical markers and machine learning. Utilizing Bruker's advanced atomic force microscopy, Cellens aims to detect bladder cancer through non-invasive urine tests. The technology has shown high sensitivity and specificity in pilot studies. This collaboration seeks to address the unmet challenges in detecting and monitoring bladder cancer and to improve patient compliance and access to care. The platform may extend to other cancers, providing a non-invasive, cost-effective alternative to current standards.
Bruker Applied Mass Spectrometry Division has unveiled new high-performance solutions at ASMS 2024, including the EVOQ® DART-TQ⁺ and ecTOF™ mass spectrometers. The EVOQ® DART-TQ⁺, a chromatography-free triple-quadrupole mass spectrometer, significantly reduces analysis times to 20 seconds per sample and cuts costs. It also offers an easy switch to LC-MS mode for water and food testing. The ecTOF™ system, a compact time-of-flight mass spectrometer, provides high-resolution GC-HRMS with simultaneous EI and CI ionization, enhancing compound identification and reducing false positives. These innovations aim to improve productivity, lower operational costs, and increase data accuracy for applied markets.
Bruker announced the release of the neofleX Imaging Profiler MALDI-TOF/TOF system, enhancing mass spectrometry imaging for tissue research. The neofleX, featuring a 10 kHz smartbeam 3D laser, offers high pixel fidelity and robust performance in various modes. It supports multiomics MSI, correlating proteins with glycans, metabolites, and now mRNA/DNA.
At the ASMS 2024 conference, researchers demonstrated the system's capability, mapping 116 proteins in a lung tissue section in 7 hours. The neofleX is compatible with MALDI-ISH and HiPLEX-IHC technologies, enhancing spatial biology research in fields like oncology and neuroscience.
The system's SCiLS Scope software facilitates easy data output and visualization, promoting collaboration in translational research.
Bruker has introduced the timsTOF Ultra 2, a highly sensitive system for advanced 4D-Proteomics, at the ASMS 2024 meeting. This system significantly enhances the ability to profile small cells and subcellular organelles, identifying and quantifying up to 50% more protein groups and 100% more peptides with very low sample amounts. The new Spectronaut 19 software further improves data analysis, enabling better protein quantitation. Bruker also launched the OmniScape software for top-down proteoform analysis and GlycoScape for real-time glycoproteomic data processing. The company has started shipping over 1,000 timsTOF systems, marking a significant milestone. Additionally, the new ENRICHplus kit from PreOmics offers a 7-fold improvement in plasma proteomics, highlighting the robustness of the timsTOF HT system.
Bruker (Nasdaq: BRKR) has announced its participation in two upcoming investor conferences: the 2024 Jefferies Global Healthcare Conference on June 6, 2024, in New York, NY, and the 45th Annual Goldman Sachs Global Healthcare Conference on June 12, 2024, in Miami, FL.
The company's top executives, including Chairman and CEO Frank Laukien and CFO Gerald Herman, will deliver presentations. Live audio webcasts of both events will be available on Bruker's Investor Relations website.
Replays of the presentations will also be accessible for at least 30 days post-event.
Bruker (Nasdaq: BRKR) has announced the pricing of its public offering of 6,000,000 shares of common stock. The underwriters have a 30-day option to purchase an additional 900,000 shares. The offering is expected to close by May 31, 2024, subject to customary conditions. Proceeds will be used to reduce debt from recent acquisitions, including repaying borrowings under the amended revolving credit agreement dated January 18, 2024. BofA Securities and J.P. Morgan are the joint underwriters. The shares may be sold on the Nasdaq Global Select Market or other venues at prevailing or negotiated prices. A final prospectus will be filed with the SEC.
Bruker (Nasdaq: BRKR) has announced a public offering of 6,000,000 shares of its common stock. The company may offer an additional 900,000 shares within 30 days based on the underwriters' decision.
The offering, managed by BofA Securities and J.P. Morgan, aims to reduce Bruker's indebtedness following recent acquisitions, specifically repaying part of its borrowings under a revolving credit agreement dated January 18, 2024.
The offering is contingent on market conditions and other customary closing requirements, with no guarantee on its completion or terms. A registration statement has been filed with the SEC and the final prospectus will be available once filed.
Bruker (Nasdaq: BRKR) will host an Investor Webinar on May 17, 2024, from 10 am to 12 noon EDT. The webinar will cover Bruker’s three recent acquisitions: Chemspeed, ELITech, and the NanoString business. Presentations will be given by CEO Frank H. Laukien, CFO Gerald Herman, and leaders of the new acquisitions. A medium-term financial outlook update will also be provided. The event will include a live Q&A session for analysts and investors. Webinar access details will be available on Bruker’s Investor Relations website, with a replay available post-event.
Bruker (Nasdaq: BRKR) has announced that its Board of Directors has approved a quarterly cash dividend of $0.05 per share.
The dividend will be paid on June 17, 2024, to stockholders who are on record as of June 3, 2024.